Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease
R. Mark Payne, Kristin M. Burns, Andrew C. Glatz, Christoph Male, Andrea Donti, Leonardo R. Brandão, Gunter Balling, Christina VanderPluym, Frances Bu’Lock, Lazaros Kochilas, Brigitte Stiller, James Cnota, Otto Rahkonen, Asra Khan, Rachele Adorisio, Șerban Stoica, Lindsay J. May, Jane C. Burns, José Francisco Kerr Saraiva, Kimberly E. McHugh, John S. Kim, Agustin Rubio, Nadia G. Chía-Vazquez, Marcie R. Meador, Joshua L. Dyme, Alison M. Reedy, Antoinette Ajavon‐Hartmann, Praneeth Jarugula, Lauren E. Carlson-Taneja, Donna Mills, Olivia Wheaton, Paul Monagle
Topics & Concepts
ApixabanMedicineInternal medicinePharmacodynamicsRandomized controlled trialWarfarinRivaroxabanAtrial fibrillationPharmacokineticsBlood Coagulation and Thrombosis MechanismsAtrial Fibrillation Management and OutcomesHeparin-Induced Thrombocytopenia and Thrombosis